• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 serosurveys for public health decision making.

作者信息

Murhekar Manoj V, Clapham Hannah

机构信息

Indian Councial of Medical Research, National Institute of Epidemiology, Chennai 600 070, India.

Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

出版信息

Lancet Glob Health. 2021 May;9(5):e559-e560. doi: 10.1016/S2214-109X(21)00057-7. Epub 2021 Mar 8.

DOI:10.1016/S2214-109X(21)00057-7
PMID:33705691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8049585/
Abstract
摘要

相似文献

1
COVID-19 serosurveys for public health decision making.用于公共卫生决策的新冠病毒血清学调查。
Lancet Glob Health. 2021 May;9(5):e559-e560. doi: 10.1016/S2214-109X(21)00057-7. Epub 2021 Mar 8.
2
Importance of Local Data and Resource Allocation for Effective Successful Public Health Interventions to Reduce COVID-19 Transmission: Commentary on COVID-19 Medical Vulnerability Indicators: A Predictive Local Data Model for Equity in Public Health Decision-Making.重视本地数据和资源配置对于有效实施公共卫生干预措施以降低 COVID-19 传播的重要性：关于 COVID-19 医疗脆弱性指标的评论：公共卫生决策中公平性的预测性本地数据模型。
Int J Environ Res Public Health. 2021 May 20;18(10):5454. doi: 10.3390/ijerph18105454.
3
Public Health Decision Making during Covid-19 - Fulfilling the CDC Pledge to the American People.新冠疫情期间的公共卫生决策——履行疾控中心对美国人民的承诺。
N Engl J Med. 2020 Sep 3;383(10):901-903. doi: 10.1056/NEJMp2026045. Epub 2020 Jul 29.
4
Improving Public Access to COVID-19 Pandemic Data in Indonesia for Better Public Health Response.改善印度尼西亚公众对新冠疫情数据的获取，以更好地应对公共卫生问题。
Front Public Health. 2020 Nov 24;8:563150. doi: 10.3389/fpubh.2020.563150. eCollection 2020.
5
Should the UK vaccinate children and adolescents against covid-19?英国应该为儿童和青少年接种新冠疫苗吗？
BMJ. 2021 Jul 23;374:n1866. doi: 10.1136/bmj.n1866.
6
Moral judgment is important in COVID-19 pandemic.道德判断在新冠疫情大流行中很重要。
J Infect Dev Ctries. 2021 May 31;15(5):615-617. doi: 10.3855/jidc.13915.
7
WICID framework version 1.0: criteria and considerations to guide evidence-informed decision-making on non-pharmacological interventions targeting COVID-19.WICID 框架 1.0 版：指导针对 COVID-19 的非药物干预措施进行循证决策的标准和考虑因素。
BMJ Glob Health. 2020 Nov;5(11). doi: 10.1136/bmjgh-2020-003699.
8
150,000 COVID-19 deaths: the price of intransigence.15万例新冠死亡病例：不作为的代价。
J R Soc Med. 2022 Jan;115(1):3. doi: 10.1177/01410768221075959.
9
Covid-19: democracy and hard choices in public health.新冠疫情：公共卫生领域的民主与艰难抉择
BMJ. 2020 Jun 5;369:m2090. doi: 10.1136/bmj.m2090.
10
COVID-19: The Shift From Clinical to Public Health Ethics.新冠疫情：从临床伦理到公共卫生伦理的转变
J Public Health Manag Pract. 2020 Jul/Aug;26(4):306-309. doi: 10.1097/PHH.0000000000001204.

引用本文的文献

1
Post-Omicron SARS-CoV-2 antibody prevalence in Sierra Leone: A cross-sectional, nationally representative, follow-up serosurvey.塞拉利昂奥密克戎变异株感染后新冠病毒抗体流行率：一项全国代表性的横断面随访血清学调查。
PLOS Glob Public Health. 2025 Apr 16;5(4):e0004273. doi: 10.1371/journal.pgph.0004273. eCollection 2025.
2
Evaluation of SARS-CoV-2 Antibody Response Between Paired Fingerprick (HemaPEN) and Venepuncture Collected Samples in Children and Adults.儿童和成人中配对的手指采血（HemaPEN）和静脉穿刺采集样本之间的新冠病毒2型抗体反应评估
Antibodies (Basel). 2025 Feb 5;14(1):13. doi: 10.3390/antib14010013.
3
Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies.追踪免疫：增加新冠病毒加强针的接种次数可延长抗受体结合域（RBD）抗体和抗RBD中和抗体的存续时间。
Vaccines (Basel). 2025 Jan 12;13(1):61. doi: 10.3390/vaccines13010061.
4
The Second Round of a Population-Based Seroprevalence Study of Anti-SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina.波斯尼亚和黑塞哥维那斯普斯卡共和国第二轮基于人群的抗SARS-CoV-2抗体血清流行率研究及新冠疫苗接种评估
Influenza Other Respir Viruses. 2025 Jan;19(1):e70053. doi: 10.1111/irv.70053.
5
The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变异株导致一所公立大学环境中的血清阳性率普遍上升。
PLOS Glob Public Health. 2025 Jan 3;5(1):e0003893. doi: 10.1371/journal.pgph.0003893. eCollection 2025.
6
High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.南非莫桑比克南部农村地区在经历了四波 COVID-19 疫情后，面临着高 SARS-CoV-2 暴露风险：基于社区的血清流行病学调查。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13332. doi: 10.1111/irv.13332.
7
Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021-February 2022.2021 年 9 月至 2022 年 2 月期间，从美国商业实验室采集的标本中社会脆弱性与 SARS-CoV-2 血清阳性率之间的关联。
Public Health Rep. 2024 Jul-Aug;139(4):501-511. doi: 10.1177/00333549231223140. Epub 2024 Feb 15.
8
Application of Machine Learning Prediction of Individual SARS-CoV-2 Vaccination and Infection Status to the French Serosurveillance Survey From March 2020 to 2022: Cross-Sectional Study.应用机器学习预测个体 SARS-CoV-2 疫苗接种和感染状态在 2020 年 3 月至 2022 年法国血清学监测调查中的应用：横断面研究。
JMIR Public Health Surveill. 2023 Nov 28;9:e46898. doi: 10.2196/46898.
9
Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.2020 年 1 月至 12 月，在世界卫生组织欧洲区域广泛推出疫苗接种计划之前，对 SARS-CoV-2 抗体血清流行率进行系统评价，并对证据进行评估。
BMJ Open. 2023 Nov 6;13(11):e064240. doi: 10.1136/bmjopen-2022-064240.
10
Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies.萨拉热窝州、波斯尼亚和黑塞哥维那联邦的献血者对 SARS-CoV-2 的血清流行率演变：横断面和纵向研究。
Influenza Other Respir Viruses. 2023 Aug 22;17(8):e13182. doi: 10.1111/irv.13182. eCollection 2023 Aug.

本文引用的文献

1
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients.SARS-CoV-2 特异性适应性免疫应答与康复期 COVID-19 重症患者。
J Clin Virol. 2021 Sep;142:104943. doi: 10.1016/j.jcv.2021.104943. Epub 2021 Aug 8.
2
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.血清学证据表明人类感染 SARS-CoV-2：系统评价和荟萃分析。
Lancet Glob Health. 2021 May;9(5):e598-e609. doi: 10.1016/S2214-109X(21)00026-7. Epub 2021 Mar 8.
3
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.尽管血清阳性率很高，巴西玛瑙斯仍出现新冠病毒的卷土重来。
Lancet. 2021 Feb 6;397(10273):452-455. doi: 10.1016/S0140-6736(21)00183-5. Epub 2021 Jan 27.
4
Antibody response to SARS-CoV-2 infection in humans: A systematic review.人类对 SARS-CoV-2 感染的抗体反应：系统综述。
PLoS One. 2020 Dec 31;15(12):e0244126. doi: 10.1371/journal.pone.0244126. eCollection 2020.
5
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.正交 SARS-CoV-2 血清学检测可用于监测低流行社区，并揭示持久的体液免疫。
Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14.
6
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.SARS-CoV-2 免疫：综述及对 3 期疫苗候选物的应用。
Lancet. 2020 Nov 14;396(10262):1595-1606. doi: 10.1016/S0140-6736(20)32137-1. Epub 2020 Oct 13.
7
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland.瑞士日内瓦基于血清学的新型冠状病毒2感染致死风险评估
Lancet Infect Dis. 2021 Apr;21(4):e69-e70. doi: 10.1016/S1473-3099(20)30584-3. Epub 2020 Jul 14.
8
Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity.用于确定 SARS-CoV-2 传播和免疫的血清流行病学研究设计。
Emerg Infect Dis. 2020 Sep;26(9):1978-1986. doi: 10.3201/eid2609.201840. Epub 2020 Jun 16.